CureVac (CVAC) said Thursday the European Patent Office upheld a modified version of its mRNA patent after dismissing most of BioNTech's (BNTX) challenge in a case tied to their dispute over vaccine technology.
A hearing to determine whether BioNTech infringed the amended patent is scheduled for July 1 in a Dusseldorf court, CureVac said.
CureVac's shares were up more than 13% in recent Friday premarket activity.